Topelia is focused on the rapid and efficient development of antiviral therapeutics targeting coronavirus infections

Learn More

About Topelia

Topelia Aust Limited (ABN 36 652 771 670) (Topelia) is an unlisted biotechnology company focused on developing and commercialising its proprietary Antiviral Triple Therapy (ATT), TPL101 for coronavirus infection.
Learn More
 

Covid-19 The Ongoing Health Risk

While most patients diagnosed with COVID-19 develop only mild to moderate disease, approximately 20% will progress to severe/critical disease state requiring medical intervention and mechanical ventilation with poor prognosis for disease resolution in severe or critical cases. These sorts of outcomes are particularly seen in the elderly and those with co-morbidities¹.

Learn More

Latest News

Why Invest?

Topelia is developing and commercialising its proprietary TPL101 Antiviral Triple Therapy (ATT) for coronavirus infection.

Read More

Therapeutics: Our partnerships and collaborations

Topelia has established strong partnerships with world-renowned experts who bring specialised knowledge and robust resources. These collaborations will play a crucial role in guiding the development of Topelia's proprietary TPL101 Antiviral Triple Therapy (ATT) for treating coronavirus infections.

Read More

Our Pipeline

Topelia is committed to advancing the development of TPL101 to fight COVID-19 infections.

With its mechanism of action targeting conserved viral proteins, TPL101 has the potential to be an adaptable treatment. Its broad-spectrum antiviral properties suggest it may be effective not only for respiratory infections like coronaviruses and influenza (including Avian Influenza) but also for other viruses from the Flaviviridae family, such as Dengue, Zika, and Yellow Fever. This makes TPL101 a promising candidate in the battle against various viral infections.

Learn More

Meet the Team

Prof Thomas Borody

Co-founder and Research Director

Dr Sabine Hazan

Co-founder and Microbiome Research Director

Dr David Fox

CEO

Mr Paul Negus

Non-executive Director

Dr Julie Simmons

Non-executive Director

Professor Robert Clancy (AM)

BSc Med (Hons) MBBS (Hons) PhD DSc FRACP FRCPA

View all team

SUBSCRIBE TO OUR NEWSLETTER

Stay in touch with us to get latest news and announcements.